UNCY - Unicycive inks licensing deal for kidney disease drug Renazorb in Asia

• Unicycive Therapeutics ( NASDAQ: UNCY ) granted exclusive rights to Lee's Pharmaceutical (HK) to develop, market and commercialize Renazorb in Mainland China, Hong Kong, and certain other Asian markets.
• Unicycive said Renazorb (lanthanum dioxycarbonate) is its novel phosphate binding agent being developed to treat hyperphosphatemia (high level of phosphate) in patients with chronic kidney disease (CKD).
• Under the agreement, Unicycive will receive $1M upfront upon signature and and up to $1M in milestones upon product launch in China and will be eligible for royalties upon regulatory and commercial achievements.
• Lee's Pharmaceutical, which is a unit of Hong Kong-based Lee's Pharmaceutical Holdings ( OTC:LPCUF ), will be responsible for developing, registration filing and approval of Renazorb in the licensed territories and will also be solely responsible for importing the drug product from Unicycive and for the costs of selling Renazorb in the regions, according to Unicycive's July 18 press release.

For further details see: